Activation of TGF-β in osteosarcoma cells leads to decreased expression of E-cadherin and increased expression of mesenchymal markers such as N-cadherin and vimentin, thereby enhancing invasive and metastatic capabilities [65]. This evidence concerns the gene CDH2 and osteosarcoma.